SCA
TPTX

Snowden Capital Advisors’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Snowden Capital Advisors’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-21
Closed -$1K – 2221
2021
Q4 		$1K Buy
+21
New +$939 ﹤0.01% 2023

Other funds holding TPTX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Snowden Capital Advisors's TPTX Position: Q1 2022 in Review

Snowden Capital Advisors sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q1 2022, closing a stake of 21 shares — an estimated $1K sold.

Snowden Capital Advisors first reported a position in TPTX in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 155 funds tracked by Wall St. Rank hold TPTX as of Q1 2022.

  • Snowden Capital Advisors reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Snowden Capital Advisors sold 21 Turning Point Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $1K.
  • Snowden Capital Advisors first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Snowden Capital Advisors's Turning Point Therapeutics, Inc. Common Stock position peaked at $1K in Q4 2021.
  • 155 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Snowden Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.